Biology Reference
In-Depth Information
117. Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting
as reversible posterior leukoencephalopathy syndrome. AJNR Am
J Neuroradiol 1998;
138. Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase
Cepsilon and protein kinase A in a model of paclitaxel-induced
painful peripheral
7.
118. Verschraegen C, Conrad CA, Hong WK. Subacute encephalo-
pathic toxicity of cisplatin. Lung Cancer 1995;
19
(3):415
e
neuropathy
in
the
rat. Neuroscience
15.
139. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful
peripheral neuropathy in the rat produced by the chemothera-
peutic drug, paclitaxel. Pain 2001;
2001;
108
(3):507
e
9.
119. Gormley PE, Gangji D, Wood JH, Poplack DG. Pharmacokinetic
study of cerebrospinal fluid penetration of cis-diamminedi-
chloroplatinum (II). Cancer Chemother Pharmacol 1981;
13
(3):305
e
304.
140. Cavaletti G, Cavalletti E, Oggioni N, et al. Distribution of pacli-
taxel within the nervous system of the rat after repeated intra-
venous administration. Neurotoxicology 2000;
94
(3):293
e
60.
120. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotox-
icity: the relationship between dosage, time, and platinum
concentration in neurologic tissues, and morphologic evidence of
toxicity. J Clin Oncol 1992;
5
(4):257
e
93.
141. Patel SR, Forman AD, Benjamin RS. High-dose ifosfamide-
induced exacerbation of peripheral neuropathy. J Natl Cancer Inst
1994;
21
(3):389
e
803.
121. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS
progenitor cells and oligodendrocytes are targets of chemother-
apeutic agents in vitro and in vivo. J Biol 2006;
10
(5):795
e
6.
142. Fathers E, Thrush D, Huson SM, Norman A. Radiation-induced
brachial plexopathy in women treated for carcinoma of the
breast. Clin Rehabil 2002;
86
(4):305
e
(7):22.
122. Rzeski W, Pruskil S, Macke A, et al. Anticancer agents are potent
neurotoxins in vitro and in vivo. Ann Neurol 2004;
5
5.
143. Olsen NK, Pfeiffer P, Johannsen L, Schroder H, Rose C. Radiation-
induced brachial plexopathy: neurological follow-up in 161
recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys
1993;
16
(2):160
e
60.
123. Wick A, Wick W, Hirrlinger J, et al. Chemotherapy-induced cell
death in primary cerebellar granule neurons but not in astrocytes:
in vitro paradigm of differential neurotoxicity.
56
(3):351
e
J Neurochem
9.
144. Tong JX, Vogelbaum MA, Drzymala RE, Rich KM. Radiation-
induced apoptosis in dorsal root ganglion neurons. J Neurocytol
1997;
26
(1):43
e
74.
124. Song TY, Chen CL, Liao JW, Ou HC, Tsai MS. Ergothioneine
protects against neuronal injury induced by cisplatin both in vitro
and in vivo. Food Chem Toxicol 2010;
2004;
91
(5):1067
e
7.
145. Crowe R, Vale J, Trott KR, Soediono P, Robson T, Burnstock G.
Radiation-induced changes in neuropeptides in the rat urinary
bladder. JUrol1996;
26
(11):771
e
9.
125. Otsuka Y, Tanaka T, Uchida D, et al. Roles of cyclin-dependent
kinase 4 and p53 in neuronal cell death induced by doxorubicin
on cerebellar granule neurons
48
(12):3492
e
6.
146. Hockerfelt U, Franzen L, Kjorell U, Forsgren S. Parallel increase
in substance P and VIP in rat duodenum in response to irradia-
tion. Peptides 2000;
156
(6):2062
e
in mouse. Neurosci Lett
5.
126. Bigotte L, Olsson Y. Cytotoxic effects of adriamycin on the central
nervous system of the mouse
2004;
365
(3):180
e
81.
147. Vasko MR, Guo C, Jiang Y, Kelley MR. Enhancing the expression
of the DNA repair/redox enzyme, Ape1/Ref-1, reduces neuro-
toxicity induced by ionizing radiation: implications for
decreasing neurocognitive dysfunction. Abstract, Pediatric
Academic Societies' Annual Meeting in Toronto. Canada;May
2007.
148. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic
inflammation. J Pharmacol Exp Ther 2002;
21
(2):271
e
cytofluorescence and electron-
microscopic observations after various modes of administration.
Acta Neurol Scand Suppl 1984;
e
67.
127. JulkaD, Sandhir R, Gill KD.Adriamycin-inducedoxidative stress in
rat central nervous system. Biochem Mol Biol Int 1993;
100
:55
e
20.
128. Bhatia AL, Manda K, Patni S, Sharma AL. Prophylactic action of
linseed (Linum usitatissimum) oil against cyclophosphamide-
inducedoxidative stress inmouse brain. JMed Food 2006;
29
(5):807
e
4.
129. Manda K, Bhatia AL. Prophylactic action of melatonin against
cyclophosphamide-induced oxidative stress in mice. Cell Biol
Toxicol 2003;
9
(2):261
e
45.
149. Brain SD. Sensory neuropeptides: their role in inflammation and
wound healing. Immunopharmacology 1997;
302
(3):839
e
52.
150. Cavaletti G, Marzorati L, Bogliun G, et al. Cisplatin-induced
peripheral neurotoxicity is dependent on total-dose intensity and
single-dose intensity. Cancer 1992;
37
(2-3):133
e
72.
130. Reiriz AB, Reolon GK, Preissler T, et al. Cancer chemotherapy
and cognitive function in rodent models: memory impairment
induced by cyclophosphamide
19
(6):367
e
7.
151. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy.
Frequent off-therapy deterioration, demyelinating syndromes,
and muscle cramps. Cancer 1990;
69
(1):203
e
in mice. Clin Cancer Res
(16). 5000; author reply -1.
131. Yang M, Kim JS, Song MS, et al. Cyclophosphamide impairs
hippocampus-dependent learning and memory in adult mice:
Possible involvement of hippocampal neurogenesis in chemo-
therapy-induced memory deficits. Neurobiol
2006;
12
23.
152. van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW,
van Houwelingen C, Neijt JP. Incidence of neuropathy in 395
patients with ovarian cancer treated with or without cisplatin.
Cancer 1990;
66
(6):1117
e
Learn Mem
94.
132. Lee GD, Longo DL, Wang Y, et al. Transient improvement in
cognitive function and synaptic plasticity in rats following cancer
chemotherapy. Clin Cancer Res 2006;
2010;
93
(4):487
702.
153. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive
paresthesias after cessation of therapy with very high-dose
cisplatin. Cancer Chemother Pharmacol 1989;
66
(8):1697
e
e
205.
133. Winocur G, Vardy J, BinnsMA, Kerr L, Tannock I. The effects of the
anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive
function in mice. Pharmacol Biochem Behav 2006;
12
(1):198
4.
154. Mollman JE, Hogan WM, Glover DJ, McCluskey LF. Unusual
presentation
25
(1):62
e
e
of
cis-platinum
neuropathy.
Neurology
75.
134. Yanovski JA, Packer RJ, Levine JD, Davidson TL, Micalizzi M,
D'Angio G. An animal model to detect the neuropsychological
toxicity of anticancer agents. Med Pediatr Oncol 1989;
85
(1):66
e
90.
155. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral
sensory neuropathy and cisplatin chemotherapy. Neurology
1984;
1988;
38
(3):488
e
21.
135. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral
neurotoxicity. Nat Rev Neurol 2010;
17
(3):216
8.
156. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC.
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic,
and toxicologic studies. Cancer 1984;
34
(7):934
e
e
66.
136. Paice JA. Chronic treatment-related pain in cancer survivors. Pain
2011;
6
(12):657
e
75.
157. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC,
Cornblath DR. Peripheral neuropathy from taxol and cisplatin
combination chemotherapy: clinical and electrophysiological
studies. Ann Neurol 1994;
54
(7):1269
e
9.
137. Cata JP, Weng HR, Dougherty PM. Behavioral and electrophysi-
ological studies in rats with cisplatin-induced chemoneuropathy.
Brain Res 2008;
152
(3 Suppl):S84
e
1230
:91
e
8.
35
(3):304
e
11.
